CEACAM5 and neoplasm: In contrast, patients who exhibited clinical benefit (CR + PR + SD) had significantly higher stromal tumor-infiltrating lymphocytes (sTILs) and CD8 T cell density in the tumor and significantly lower cancer antigen 15–3 and carcinoembryonic antigen serum levels at baseline compared to the patients with progressive disease.